BC Week In Review | Mar 14, 2016
Clinical News

Danegaptide: Phase II data

Top-line data from a double-blind, Danish Phase II trial in about 591 patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) showed that a single infusion of danegaptide missed the primary...
BC Innovations | Jul 31, 2014
Translation in Brief

Translational tidbits

Benjamin Boettner, Associate Editor, and Chris Cain, Michael J. Haas and Kai-Jye Lou, Senior Writers  Quantitative boost for CSHL The Simons Foundation has donated $50 million to Cold Spring Harbor Laboratory to establish the Simons...
BC Week In Review | Jul 14, 2014
Company News

Zealand Pharma, University of Copenhagen deal

Zealand partnered with the University of Copenhagen to elucidate the cell protective properties and therapeutic potential of danegaptide . Zealand said the collaboration, which is in the form of an industrial post-doctoral project, has been selected...
BC Week In Review | Nov 25, 2013
Clinical News

Danegaptide: Phase II started

Zealand began a double-blind, placebo-controlled, Danish Phase II trial to evaluate 2 doses of danegaptide in combination with balloon dilatation in >=600 patients. Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark   Product: Danegaptide ( ZP1609 ) (formerly GAP-134)...
BioCentury | Nov 22, 2010

Smaller-Still Big

Smaller - still big Zealand Pharma A/S was slated to start trading last Friday; instead the company lowered the amount it plans to raise in its IPO. The first day of trading is now set for...
BC Extra | Nov 20, 2010
Financial News

Zealand trims proposed IPO

Zealand Pharma A/S (Glostrup, Denmark) now hopes to raise up to DKK447.5 million ($81.8 million) in its IPO on the Copenhagen Stock Exchange and a private placement after lowering the number of shares and the...
BioCentury | Feb 2, 2009

Limbo dancing

Pfizer Inc. 's decision to acquire Wyeth rippled quickly through the biotech industry, as Crucell N.V. announced that Wyeth withdrew from discussions regarding a potential combination of the two companies. While most of Wyeth's partners...
BioCentury | Dec 17, 2007

Atrial fibrillation pipeline

Atrial fibrillation pipeline Atrial fibrillation pipeline Selected compounds in development for atrial fibrillation (AF). Company Product Description Indication Status Cardiome/Astellas Kynapid vernakalant Intravenous mixed ion channel antagonist AF Under review Solvay Pulzium tedisamil Intravenous multiple...
BC Week In Review | Oct 15, 2007
Clinical News

ZP1609: Phase I started

Zealand began a U.S. Phase I trial of oral ZP1609, which triggered an undisclosed milestone payment from WYE. The companies partnered to co-develop gap junction modifiers for cardiovascular disorders in 2003 (see BioCentury, May 5,...
Items per page:
1 - 9 of 9